Medicenna
Vancouver
British Columbia
Canada
135 articles about Medicenna
-
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
7/27/2022
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced new clinical data on safety, pharmacodynamics and anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s long-acting IL-2 super agonist.
-
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights
6/22/2022
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the fiscal year ended March 31, 2022.
-
Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent
6/9/2022
Patent covers composition and methods of treating degenerative diseases via administration of IL-4 and IL-13 Empowered Superkines.
-
Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022
6/7/2022
Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on June 22, 2022 at 8:30 AM ET to report its fiscal year 2022 financial results and operational highlights.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting
5/11/2022
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that clinical data from the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study of MDNA11.
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study
5/2/2022
Medicenna Therapeutics Corp. today announced new clinical data from the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study of MDNA11, the Company’s long-acting IL-2 super-agonist.
-
Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
4/27/2022
Medicenna Therapeutics Corp. announced that Dr. Fahar Merchant, President and CEO and Elizabeth Williams, CFO of Medicenna, will attend the conference and present a corporate overview at the 2022 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place from May 2 – May 3, 2022.
-
Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting
4/8/2022
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced new preclinical data on its long-acting IL-13 super-antagonist, Fc-MDNA413, in an electronic poster at the American Association for Cancer Research Annual Meeting.
-
Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting
4/8/2022
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced new preclinical data highlighting the potent anti-tumor efficacy of the next-generation BiSKIT, anti-PD1-MDNA109FEAA, in an electronic poster at the American Association for Cancer Research Annual Meeting.
-
Medicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
3/10/2022
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference, which is scheduled to take place virtually from March 15 – March 17, 2022.
-
Medicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor
3/3/2022
Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2
-
Medicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational Highlights
2/9/2022
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced its financial results and operational highlights for the quarter ended December 31, 2021.
-
Medicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9, 2022
2/2/2022
Medicenna Therapeutics Corp. today announced that it will host a conference call and live webcast on February 9, 2022 at 8:30 AM ET to report its third quarter fiscal 2022 financial results and operational highlights.
-
Medicenna Announces Formation of its Scientific Advisory Board
1/31/2022
Medicenna Therapeutics Corp. today announced the formation of its Scientific Advisory Board (SAB) comprised of thought leaders in cancer immunotherapy, immuno-engineering and immune monitoring.
-
Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer
1/26/2022
Medicenna Therapeutics Corp. today announced the peer-reviewed publication of preclinical data on MDNA11.
-
Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee
1/17/2022
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that Mann Muhsin has resigned as Chief Medical Officer of the Company to assume a position closer to home.
-
Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study
12/22/2021
Medicenna Therapeutics Corp. today announced preliminary data from the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study of MDNA11, the Company’s selective, long-acting and novel IL-2 super-agonist.
-
Medicenna Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada
12/17/2021
Medicenna Therapeutics Corp. today announced that Health Canada has approved the expansion of the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study of MDNA11, the Company’s long-acting, “beta-only” IL-2 super-agonist, to clinical trial sites in Canada.